Vesicle-associated membrane protein-associated proteins (VAPs) establish membrane contact sites (MCS) between the endoplasmic reticulum (ER) and other organelles through interactions with FFAT-containing proteins, coordinating lipid synthesis, transfer, and metabolism. Their tissue-specific functions remain poorly understood. We report a patient with a homozygous nonsense variant in VAPA (p.(Glu12( *))), presenting with profound global developmental delay and progressive surfactant dysfunction leading to cholesterol pneumonitis and pulmonary fibrosis. Alternative translation initiation partially bypasses the premature stop codon, producing an N-terminally truncated VAPA protein with impaired FFAT binding capacity and disrupted lamellar body (LB) formation in human alveolar type 2 cells. We identify the pulmonary disease-associated ATP-binding cassette transporter A3 (ABCA3), a regulator of surfactant lipid accumulation, as a VAPA interactor. VAPA-ABCA3 interaction facilitates lipid exchange at previously uncharacterized ER-LB MCSs, a function lost upon VAPA truncation. Our findings establish VAPA-dependent MCS dysfunction as a mechanism of syndromic lung disease and define a pathway for surfactant lipid trafficking.
Keywords
